PECORA, IRENE
 Distribuzione geografica
Continente #
NA - Nord America 426
EU - Europa 240
AS - Asia 116
AF - Africa 53
Totale 835
Nazione #
US - Stati Uniti d'America 426
IT - Italia 93
SE - Svezia 78
SG - Singapore 58
CI - Costa d'Avorio 35
CN - Cina 33
BG - Bulgaria 17
GB - Regno Unito 16
AT - Austria 14
DE - Germania 11
NG - Nigeria 10
IN - India 8
SN - Senegal 8
TR - Turchia 7
HK - Hong Kong 4
VN - Vietnam 4
PL - Polonia 3
FR - Francia 2
IE - Irlanda 2
CZ - Repubblica Ceca 1
FI - Finlandia 1
JP - Giappone 1
LK - Sri Lanka 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 835
Città #
Chandler 65
Fairfield 48
Abidjan 35
Singapore 31
Ashburn 26
Seattle 26
New York 24
Woodbridge 23
Wilmington 20
Milan 18
Santa Clara 18
Sofia 17
Boardman 16
Cambridge 16
Florence 16
Vienna 14
Lawrence 12
Princeton 12
London 11
Pisa 11
Lagos 10
Ann Arbor 9
Houston 9
Beijing 8
Dakar 8
Istanbul 7
Medford 7
Fuzhou 6
Shanghai 6
Bremen 5
Hyderabad 5
Kent 5
Ogden 5
Hong Kong 4
Piombino 4
Frankfurt am Main 3
Los Angeles 3
Ansbach 2
Changsha 2
Dublin 2
Norwalk 2
Philadelphia 2
Quanzhou 2
Romainville 2
San Diego 2
Serra 2
Warsaw 2
Casaleone 1
Chiswick 1
Council Bluffs 1
Des Moines 1
Elk Grove Village 1
Formigine 1
Fulham 1
Garbagnate Milanese 1
Hefei 1
Islington 1
Jinan 1
Lappeenranta 1
Livorno 1
Massa 1
Minerbio 1
Minneapolis 1
New Delhi 1
Olomouc 1
Pietrasanta 1
Redmond 1
Redwood City 1
Rome 1
Rosignano Marittimo 1
Stuttgart 1
Taizhou 1
Vicenza 1
Vicopisano 1
Washington 1
Yokohama 1
Totale 612
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 116
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 95
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 83
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 81
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 75
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 64
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 50
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 47
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 45
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 43
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 40
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 34
Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors 31
The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study 23
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 15
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 10
Totale 852
Categoria #
all - tutte 4.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.146


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202069 0 0 0 0 8 9 9 9 8 5 18 3
2020/202177 5 2 4 5 0 19 4 5 10 4 9 10
2021/2022115 0 0 1 3 18 25 0 3 9 11 7 38
2022/2023282 29 48 22 12 30 27 2 27 61 0 22 2
2023/2024162 14 14 22 10 18 25 12 11 3 3 12 18
2024/2025116 5 25 18 48 20 0 0 0 0 0 0 0
Totale 852